The High-Dose Melatonin Protocol of Dr. Paolo Lissoni: Neuroimmunomodulation in Integrative Oncology

The High-Dose Melatonin Protocol, developed by Italian oncologist and researcher Dr. Paolo Lissoni, represents a foundational approach in psychoneuroimmunoendocrinology-based cancer therapy. Developed over three decades of clinical research beginning in the 1980s, the protocol utilizes pharmacological doses of the pineal hormone melatonin, typically 20 mg to 100 mg daily, as an immunomodulating and cytoprotective agent in patients with advanced solid tumors. This essay explores the scientific rationale for high-dose melatonin, the clinical evidence generated by Lissoni's research group, the multiple mechanisms of action including direct antitumor effects, chemotherapy sensitization, and immune restoration, and the practical considerations for implementation based on decades of published clinical trials.

---

1. Introduction: The Pioneer of Psychoneuroimmunoendocrinology

Dr. Paolo Lissoni is an Italian physician and researcher whose work over the past four decades has established him as a pioneering figure in the field of psychoneuroimmunoendocrinology as applied to cancer treatment. Based at the Institute of Biological Medicine in Milan and previously affiliated with the San Gerardo Hospital in Monza, Lissoni recognized early in his career that the conventional approach to oncology, focused exclusively on cytotoxic therapies, neglected the profound influence of the neuroendocrine system on immune function and tumor behavior .

Drawing on emerging evidence that the pineal gland and its primary hormone melatonin play a significant role in regulating circadian rhythms, immune function, and tumor growth, Lissoni initiated a systematic program of clinical investigation beginning in the mid-1980s. His 1987 publication in Tumori, "Clinical Study of Melatonin in Untreatable Advanced Cancer Patients," represents one of the first modern clinical trials of melatonin in oncology and established the foundation for three decades of subsequent research .

Lissoni's work is distinctive for its integration of multiple therapeutic modalities within a unified conceptual framework. Rather than viewing melatonin as a standalone treatment, he developed combination protocols incorporating low-dose interleukin-2, opioid antagonists such as naltrexone, and other pineal indoles like 5-methoxytryptamine, all designed to work synergistically to restore anticancer immunity . His research also uniquely explored the relationship between patient psychospiritual status and therapeutic response, anticipating current interest in mind-body medicine by several decades .

2. The Foundational Philosophy: Cancer as Neuroimmune Dysregulation

The High-Dose Melatonin Protocol is built upon a fundamental conceptual shift in understanding cancer progression. Lissoni's framework posits that malignant growth is not merely a local cellular phenomenon but reflects a systemic failure of neuroimmune regulation, particularly involving the pineal gland and its hormonal products.

In healthy individuals, the pineal gland orchestrates circadian rhythms through the nocturnal secretion of melatonin, which in turn regulates immune function, antioxidant defenses, and cellular proliferation. Cancer patients, however, frequently exhibit profound disruptions in this system. Alterations in melatonin secretion patterns have been documented across multiple tumor types, and these abnormalities correlate with disease progression, impaired immune function, and poorer clinical outcomes .

Lissoni recognized that these neuroendocrine disturbances are not merely epiphenomena but active contributors to tumor growth. The loss of normal pineal function removes a critical endogenous brake on malignant proliferation while simultaneously compromising the immune system's ability to recognize and eliminate cancer cells. Therapeutic administration of high-dose melatonin, therefore, represents an attempt to restore this missing regulatory signal, reestablishing normal circadian and immune function and creating a host environment less permissive for tumor growth.

This framework explains why Lissoni's protocols consistently use pharmacological doses far exceeding the amounts used for sleep support. While physiological melatonin production results in peak blood levels measured in picograms per milliliter, therapeutic doses of 20 mg to 100 mg daily produce concentrations several orders of magnitude higher, levels required to achieve the immunomodulatory, proapoptotic, and antiangiogenic effects that are not engaged at physiological concentrations .

3. The Central Agent: Melatonin at Pharmacological Doses

Melatonin is an indoleamine hormone synthesized primarily in the pineal gland from the amino acid tryptophan through a pathway involving serotonin. Its synthesis is regulated by the suprachiasmatic nucleus in response to light exposure, with darkness stimulating production and light suppressing it. The hormone is released directly into the bloodstream and cerebrospinal fluid, reaching peak levels during the night and playing a central role in coordinating circadian rhythms throughout the body .

At physiological concentrations, melatonin acts primarily through high-affinity membrane receptors, designated MT1 and MT2, which are G-protein coupled receptors expressed in multiple tissues including the suprachiasmatic nucleus, retina, and various peripheral organs. Activation of these receptors modulates cyclic AMP signaling and influences circadian clock gene expression .

However, at the pharmacological doses used in Lissoni's protocols, additional mechanisms come into play that are not engaged at physiological levels. High-dose melatonin exerts direct antioxidant effects independent of receptor binding, scavenging free radicals and upregulating antioxidant enzyme systems. It also interacts with nuclear receptors of the ROR/RZR family, influencing gene expression related to immune function and cell proliferation. Perhaps most importantly for cancer therapy, high concentrations of melatonin have been shown to induce apoptosis in malignant cells, inhibit angiogenesis, and modulate immune cell activity in ways that are not observed at lower doses .

The concept of hormesis is relevant here: a substance that at low concentrations exerts subtle regulatory effects can, at higher concentrations, trigger fundamentally different biological responses that can be harnessed therapeutically. Lissoni's clinical research systematically explored this pharmacological territory, establishing dose-response relationships and optimal timing of administration to maximize therapeutic benefit while maintaining an exceptional safety profile.

4. Comprehensive Mechanisms of Action

The therapeutic effects of high-dose melatonin in cancer patients arise from multiple well-characterized mechanisms that have been documented in both preclinical studies and Lissoni's clinical investigations.

Direct Antitumor Effects

Melatonin exerts direct antiproliferative effects on cancer cells through several pathways. It modulates estrogen receptor signaling, functioning as a selective estrogen receptor modulator that downregulates both ER-alpha and ER-beta expression and reduces estrogen binding to these receptors. This mechanism is particularly relevant in hormone-dependent malignancies such as breast cancer .

Melatonin also induces apoptosis through activation of the p53 tumor suppressor pathway and modulation of mitochondrial membrane potential. Studies have demonstrated that melatonin treatment upregulates proapoptotic proteins while downregulating antiapoptotic factors, shifting the balance toward programmed cell death in malignant cells. Additionally, melatonin inhibits telomerase activity, potentially contributing to reduced proliferative capacity of cancer cells .

Anti-angiogenic Activity

Tumor growth beyond minimal size requires the recruitment of new blood vessels through angiogenesis. Melatonin has been shown to inhibit this process through multiple mechanisms, including suppression of vascular endothelial growth factor expression and modulation of hypoxia-inducible factor activity. By starving tumors of their blood supply, melatonin contributes to long-term disease control .

Immune Modulation

A central focus of Lissoni's research has been melatonin's ability to restore and enhance anticancer immunity. Cancer patients commonly exhibit lymphocytopenia, a reduction in lymphocyte count that correlates with poor prognosis and shorter survival. Melatonin administration has been shown to increase lymphocyte counts and improve the functional activity of natural killer cells and cytotoxic T lymphocytes .

This immunomodulatory effect is particularly important when melatonin is combined with interleukin-2, the primary growth factor for lymphocytes. Lissoni's research demonstrated that the combination of low-dose interleukin-2 and high-dose melatonin could normalize lymphocyte counts in a majority of patients with advanced cancer-related lymphocytopenia, with 64% of patients achieving normalization in one study .

Chemotherapy Sensitization and Toxicity Reduction

One of the most clinically significant findings from Lissoni's research is melatonin's ability to enhance the efficacy of chemotherapy while simultaneously reducing its toxicity. In a landmark study involving 250 metastatic solid tumor patients randomized to receive chemotherapy alone or chemotherapy plus melatonin at 20 mg daily, the objective tumor response rate was significantly higher in the melatonin group (42 of 124 patients versus 19 of 126 patients, p < 0.001). The one-year survival rate was similarly improved, with 63 of 124 patients surviving in the melatonin group compared to only 29 of 126 in the control group .

Equally important was the reduction in chemotherapy-related toxicity. Patients receiving melatonin experienced significantly lower rates of thrombocytopenia, neurotoxicity, cardiotoxicity, stomatitis, and asthenia. This dual effect enhanced efficacy with reduced toxicity is unusual in oncology, where treatments that increase tumor response typically come with increased side effects .

Antioxidant Protection of Normal Tissues

Melatonin is one of the most potent endogenous antioxidants known, capable of directly scavenging free radicals and upregulating antioxidant enzyme systems including superoxide dismutase, glutathione peroxidase, and catalase. At pharmacological doses, this antioxidant activity provides selective protection to normal tissues against the oxidative damage caused by chemotherapy and radiation, while malignant cells, with their impaired antioxidant defenses, remain vulnerable or become more sensitive to treatment-induced oxidative stress .

5. The Clinical Evidence Base

Lissoni's research program has produced a substantial body of clinical evidence spanning more than three decades, including multiple randomized controlled trials and numerous case series documenting the effects of high-dose melatonin in cancer patients.

The 1987 Foundational Study

Lissoni's initial clinical investigation, published in Tumori in 1987, included 19 patients with advanced solid tumors that had failed to respond to standard therapies. Melatonin was administered intramuscularly at 20 mg daily, followed by maintenance dosing in patients who achieved remission, disease stabilization, or performance status improvement. Among patients with better initial performance status, one partial response was observed in pancreatic cancer, five patients achieved disease stabilization, and six of ten patients experienced improved performance status. This preliminary study established both the feasibility of high-dose melatonin administration and the potential for clinical benefit even in heavily pretreated patients .

Chemotherapy Combination Trials

The most robust evidence for high-dose melatonin comes from the 1999 randomized trial published in the European Journal of Cancer, involving 250 patients with metastatic solid tumors including lung, breast, gastrointestinal, and head and neck cancers. Patients were randomized to receive chemotherapy alone or chemotherapy plus oral melatonin at 20 mg daily. The melatonin group demonstrated significantly higher tumor response rates (33.9% versus 15.1%) and one-year survival (50.8% versus 23.0%). The consistency of benefit across multiple tumor types suggests that melatonin's effects are not limited to specific histologies but reflect fundamental modulation of host-tumor interactions .

Lung Cancer Studies

A subsequent study focused specifically on metastatic non-small cell lung cancer, enrolling 50 patients receiving chemotherapy plus melatonin and comparing outcomes with 100 control patients receiving chemotherapy alone. The tumor response rate was significantly higher in the melatonin group (21 of 50 patients versus 24 of 100, p < 0.001). This study also generated the intriguing finding that response rates were highest in patients characterized as having "spiritual faith," with 6 of 8 such patients achieving objective tumor regression compared to 15 of 42 patients with other psychological profiles. This observation, while preliminary, suggests that the psychospiritual status of patients may modulate biological responses to neuroimmunomodulatory therapy .

Combination with Interleukin-2

Lissoni extensively investigated combinations of melatonin with low-dose interleukin-2 as a strategy to restore anticancer immunity. In a 2002 study, 14 patients with untreatable metastatic solid tumors received interleukin-2 plus melatonin, with or without the opioid antagonist naltrexone. The combination of all three agents produced significantly greater lymphocytosis than interleukin-2 plus melatonin alone, demonstrating that multiple neuroimmunomodulatory agents can be combined synergistically .

A 2020 study addressed the specific problem of cancer-related lymphocytopenia, a condition associated with poor prognosis for which no standard treatment exists. Fourteen patients with persistent lymphocytopenia received melatonin at 100 mg daily plus subcutaneous low-dose interleukin-2. Normalization of lymphocyte count was achieved in 64% of patients, with 29% responding within the first week of therapy. This study documented that even very high melatonin doses (100 mg daily) are well tolerated and can produce clinically meaningful immune restoration .

Radiation Protection

Lissoni also investigated whether melatonin could protect against radiation-induced lymphocytopenia, a common complication of pelvic irradiation for rectal and cervical cancers. In a randomized study, patients receiving interleukin-2 during radiation therapy experienced significantly less lymphocyte decline than those receiving melatonin alone or melatonin plus 5-methoxytryptamine. While melatonin alone was insufficient to fully protect against radiation effects, the study demonstrated the feasibility of combining multiple pineal strategies .

6. The Protocol in Practice: Dosing and Administration

Based on Lissoni's published research, the High-Dose Melatonin Protocol follows specific guidelines for dosing and timing that appear critical to achieving therapeutic effects.

Standard Dosing

The most extensively studied dose in Lissoni's research is 20 mg administered orally each evening. This dose was used in the large randomized chemotherapy combination trials and has the strongest evidence base for improving tumor response and survival .

Higher Dose Protocols

For patients with more advanced disease or specific indications such as refractory lymphocytopenia, Lissoni investigated higher doses up to 100 mg daily. This dose was used in combination with interleukin-2 and was well tolerated, with no serious adverse events reported .

Timing of Administration

The timing of melatonin administration is critical due to its role in circadian regulation. Lissoni's protocols consistently specify evening administration, typically at bedtime, to synchronize with the natural nocturnal peak of endogenous melatonin secretion. This timing optimizes circadian effects and may enhance therapeutic efficacy.

Combination Strategies

In Lissoni's framework, melatonin is often used as part of broader neuroimmunotherapeutic combinations. These include:

· Low-dose interleukin-2 administered subcutaneously at 1.8 to 3 million IU per day in cyclic schedules

· Naltrexone at 100 mg every other day to modulate opioid receptor signaling

· 5-methoxytryptamine, another pineal indole, for additional immunomodulatory effects

7. Safety Profile and Tolerability

One of the most remarkable aspects of the High-Dose Melatonin Protocol is its exceptional safety profile, particularly when compared to conventional anticancer therapies.

In Lissoni's 1999 study involving 124 patients receiving melatonin at 20 mg daily for extended periods, no significant toxicity attributable to melatonin was reported. The reduction in chemotherapy-related side effects in the melatonin group actually resulted in improved tolerability compared to chemotherapy alone .

The 2020 study using 100 mg daily similarly reported no serious adverse events, with the higher dose being well tolerated . This safety profile is consistent with the broader literature on melatonin, which has documented an extremely wide therapeutic window. The median lethal dose in animal studies is thousands of times higher than the human therapeutic dose, and human studies have administered doses up to 6.6 grams daily without serious toxicity.

The most commonly reported side effects of high-dose melatonin include drowsiness, headache, and transient dizziness, effects that are generally mild and resolve with continued use or dose adjustment. The evening administration timing minimizes daytime sedation and may actually improve sleep quality, a significant benefit for cancer patients who commonly experience sleep disturbances.

8. Scientific Context and Integration with Conventional Oncology

The High-Dose Melatonin Protocol should be understood within the broader context of psychoneuroimmunology and integrative oncology. Lissoni's work anticipated by decades the current recognition that host factors including circadian rhythm, immune function, and psychological state significantly influence cancer outcomes.

The mechanisms elucidated in Lissoni's research have been confirmed and extended by subsequent investigators. A 2025 review article in the Chonnam Medical Journal summarized the current understanding of melatonin's anticancer effects, confirming its roles in inducing apoptosis, inhibiting angiogenesis, suppressing metastasis, and modulating epigenetic mechanisms including DNA methylation and telomere length regulation. The review noted that doses of 3 to 20 mg daily have shown preclinical efficacy, with higher doses up to 20 mg or more used clinically in combination with chemotherapy .

A 2022 review in the Journal of Pineal Research similarly confirmed melatonin's ability to regulate microRNA networks involved in cancer, with effects documented in breast, gastric, oral, colorectal, prostate, and other malignancies .

The relationship between melatonin and the Warburg effect, cancer cells' reliance on aerobic glycolysis, has been explored as a potential mechanism for selective antitumor activity. Melatonin suppresses the aerobic metabolism of tumors while enhancing oxidative metabolism in normal tissues, creating a metabolic environment unfavorable for malignant proliferation .

9. The Psychospiritual Dimension

One of the most distinctive aspects of Lissoni's research is his exploration of the relationship between patient psychospiritual status and therapeutic response to melatonin. The 2010 study in metastatic lung cancer patients found that objective tumor response rates were significantly higher in patients characterized as having "spiritual faith" compared to those with other psychological profiles including anxiety, apathy, or accusatory behavior .

This finding, while preliminary and requiring confirmation in larger studies, is consistent with a growing body of research documenting relationships between psychological factors and cancer outcomes. Lissoni interpreted these results within his psychoneuroimmunoendocrinological framework, suggesting that positive psychological and spiritual states may enhance neuroimmune function and amplify the effects of immunomodulatory therapies.

The clinical implication is not that patients without spiritual faith cannot benefit from melatonin, as many such patients in Lissoni's studies did achieve objective responses. Rather, the observation suggests that comprehensive cancer care should attend to the whole person, including psychological and spiritual dimensions, as these factors may influence biological responses to treatment.

10. Conclusion

The High-Dose Melatonin Protocol developed by Dr. Paolo Lissoni represents one of the most thoroughly investigated integrative oncology approaches in the medical literature. Spanning more than three decades of clinical research, including randomized controlled trials involving hundreds of patients, Lissoni's work has established that pharmacological doses of this pineal hormone can enhance chemotherapy efficacy, reduce treatment toxicity, restore anticancer immunity, and improve quality of life in patients with advanced solid tumors.

The scientific foundation for these effects is robust and multifaceted. Melatonin at high doses exerts direct antiproliferative and proapoptotic effects on cancer cells, inhibits angiogenesis, modulates estrogen receptor signaling, enhances immune function through lymphocyte stimulation, and provides selective antioxidant protection to normal tissues. These mechanisms converge to create a host environment less permissive for tumor growth and more responsive to conventional cytotoxic therapies.

The safety profile of high-dose melatonin is exceptional, with doses up to 100 mg daily producing no serious adverse events in clinical studies. This favorable risk-benefit ratio stands in sharp contrast to most conventional cancer therapies and positions melatonin as an attractive adjunctive agent for patients across a wide range of tumor types and clinical stages.

Several important considerations emerge from Lissoni's research. The optimal dose appears to be 20 mg daily for most patients, with higher doses reserved for specific indications such as refractory lymphocytopenia. Evening administration is critical to synchronize with circadian physiology. Combination with other neuroimmunomodulatory agents including low-dose interleukin-2 and naltrexone may produce synergistic effects in appropriately selected patients. And the psychospiritual status of patients may influence therapeutic response, suggesting the importance of comprehensive, whole-person approaches to cancer care.

The limitations of the evidence base must be acknowledged. Most of Lissoni's studies, while including randomized designs, involved relatively small sample sizes by contemporary standards. The research was conducted primarily by a single investigative group and has not been extensively replicated in multicenter trials. The mechanistic understanding, while substantially advanced since Lissoni's early work, continues to evolve.

Nevertheless, for patients with advanced cancer seeking to optimize conventional treatment outcomes, improve quality of life, and support their body's innate anticancer defenses, the High-Dose Melatonin Protocol offers a well-tolerated, evidence-based option. Lissoni's pioneering work reminds us that the neuroendocrine system, often neglected in conventional oncology, represents a rich terrain for therapeutic intervention. By restoring the regulatory signals that cancer disrupts, we may be able to tip the balance toward host resistance and improve outcomes even in patients with advanced disease.

11. Key Published Works and Resources

Foundational Publications:

· Lissoni P, et al. Clinical Study of Melatonin in Untreatable Advanced Cancer Patients. Tumori. 1987;73(5):475-480

· Lissoni P, et al. Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. Eur J Cancer. 1999;35(12):1688-1692

Combination Therapy Research:

· Lissoni P, et al. Neuroimmunotherapy of untreatable metastatic solid tumors with subcutaneous low-dose interleukin-2, melatonin and naltrexone. Neuro Endocrinol Lett. 2002;23(4):341-344

· Lissoni P, et al. A study of immunoendocrine strategies with pineal indoles and interleukin-2 to prevent radiotherapy-induced lymphocytopenia. In Vivo. 2008;22(3):397-400

· Lissoni P, et al. A Short-Period Therapy with Subcutaneous Low-Dose IL-2 Plus High-Dose Melatonin to Correct Advanced Cancer-Related Lymphocytopenia. Psychoneuroimmunology J. 2020;1:1-4

Mechanistic Reviews:

· Bjørklund G, et al. Insights on Melatonin as an Active Pharmacological Molecule in Cancer Prevention. Curr Med Chem. 2019;26(34)

· Nemati Motehaver A, et al. Melatonin and Breast Cancer: A Review Article. Chonnam Med J. 2025;61(2):63-74